Clinical Trials
51 trialsMulti-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
City of Hope Medical Center
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
M.D. Anderson Cancer Center
ATACC AML
Baylor College of Medicine
Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML
First Affiliated Hospital of Guangxi Medical University
UHKT-CAR123-01
Institute of Hematology and Blood Transfusion, Czech Republic
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
Baylor College of Medicine
CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia
Zhejiang University
The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT
Institute of Hematology & Blood Diseases Hospital, China
INA03
Institut Paoli-Calmettes
XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia
Shanghai Jiao Tong University School of Medicine
Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Thomas Jefferson University
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
University of Pittsburgh
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
University of Rochester
The Role and Mechanism of TCR-T Cells in Immunotherapy for Acute Myeloid Leukemia
Shenzhen University General Hospital
Off-the-shelf CD123 CAR-NK for R/R AML
Peking University People's Hospital
Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.
First Affiliated Hospital of Zhejiang University
Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia
Hrain Biotechnology Co., Ltd.
A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia
Zhejiang University
iNK-r/r AML
Guangzhou Ruixin Biotechnological Co., LTD
EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia
The Second Hospital of Anhui Medical University
Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
The First Affiliated Hospital of Soochow University
Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia
Base Therapeutics (Shanghai) Co., Ltd.
Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia
Base Therapeutics (Shanghai) Co., Ltd.
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
University of Chicago
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Amgen
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers
Roswell Park Cancer Institute
Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCT
Xuzhou Medical University
Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia
Wuxi People's Hospital
Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
Jazz Pharmaceuticals
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
Zhejiang University
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
Northwestern University
Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Xinqiao Hospital of Chongqing
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
iCell Gene Therapeutics
NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
Zhejiang University
Intra-Osseous Co-Transplant of UCB and hMSC
Case Comprehensive Cancer Center
IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia
Zhejiang University
Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment
University of Freiburg
CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
iCell Gene Therapeutics
Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia
University of Pittsburgh
CD123 Redirected Autologous T Cells for AML
University of Pennsylvania
GVHD
Washington University School of Medicine